CervoMed

CervoMed EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of CervoMed (CRVO) as of Oct 26, 2026 is -0.78. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -0.01 — a change of 5,222.92% (lower).

EV/OCF

-0.78

YoY

5,222.92%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of CervoMed is 2025 -0.78 . EV/OCF (Enterprise Value to Operating Cash Flow) of CervoMed was 2024 -0.01 . It decreases by 5,222.92% lower compared to the previous year.

The CervoMed EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-2.89 USD
Jan 1, 2019
-2.56 USD
Jan 1, 2020
-1.53 USD
Jan 1, 2021
-0.82 USD
Jan 1, 2022
-18.46 USD
Jan 1, 2023
-4.21 USD
Jan 1, 2024
-0.01 USD
Jan 1, 2025
-0.78 USD
The CervoMed EV/OCF history
YEAREV/OCFYoY
-0.78+5,222.92%
-0.01-99.65%
-4.21-77.18%
-18.46+2,153.79%
-0.82-46.64%
-1.53-40.05%
-2.56-11.54%
-2.89+15.80%
-2.50-32.80%
-3.72-49.80%
-7.41+287.09%
-1.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CervoMed Stock analysis

What does CervoMed do? CervoMed Inc. generates revenue through the development and clinical advancement of its lead product candidate, neflamapimod, a small molecule brain penetrant targeting p38MAP kinase alpha. The company focuses on clinical-stage therapeutics for degenerative brain diseases, with neflamapimod in Phase IIb trials for dementia with Lewy Bodies (DLB), early Alzheimer’s disease, and stroke recovery. Its wholly owned subsidiary, EIP Pharma Inc., supports these efforts. CervoMed targets medical institutions and research organizations involved in neurodegenerative disease treatment, seeking partnerships for clinical trials and future commercialization. The company's primary product, neflamapimod, is designed to address synaptic dysfunction in neurodegenerative disorders, positioning it for potential disease-modifying treatments in DLB and related conditions. CervoMed's clinical development strategy centers on advancing this candidate through Phase IIb studies, aiming to secure regulatory approvals and eventual market entry. The firm's operations are structured around its subsidiary, EIP Pharma Inc., which handles specific therapeutic development tasks. CervoMed Inc. operates as a clinical-stage biotechnology company, relying on the progress of its lead candidate to attract investment and strategic collaborations. Its focus on CNS-focused therapeutics for degenerative brain diseases aligns with unmet medical needs in neurology, targeting healthcare providers and pharmaceutical partners interested in innovative treatments for conditions like DLB and Alzheimer’s disease. CervoMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CervoMed stock

EV/OCF (Enterprise Value to Operating Cash Flow) of CervoMed is -0.78 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of CervoMed changed from -0.01 to -0.78, representing a 5,222.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) CervoMed since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s CervoMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — CervoMed

All Key Metrics — CervoMed